GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kymera Therapeutics Inc (NAS:KYMR) » Definitions » Shares Outstanding (Diluted Average)

Kymera Therapeutics (Kymera Therapeutics) Shares Outstanding (Diluted Average) : 70.77 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kymera Therapeutics Shares Outstanding (Diluted Average)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Kymera Therapeutics's average diluted shares outstanding for the quarter that ended in Mar. 2024 was 70.77 Mil.


Kymera Therapeutics Shares Outstanding (Diluted Average) Historical Data

The historical data trend for Kymera Therapeutics's Shares Outstanding (Diluted Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kymera Therapeutics Shares Outstanding (Diluted Average) Chart

Kymera Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (Diluted Average)
Get a 7-Day Free Trial 30.20 17.35 47.99 53.93 58.37

Kymera Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (Diluted Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.19 58.33 58.42 58.52 70.77

Kymera Therapeutics Shares Outstanding (Diluted Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Kymera Therapeutics  (NAS:KYMR) Shares Outstanding (Diluted Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Kymera Therapeutics Shares Outstanding (Diluted Average) Related Terms

Thank you for viewing the detailed overview of Kymera Therapeutics's Shares Outstanding (Diluted Average) provided by GuruFocus.com. Please click on the following links to see related term pages.


Kymera Therapeutics (Kymera Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, USA, 02472
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Executives
Jeffrey W. Albers director BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Ellen Chiniara officer: Chief Legal Officer 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jeremy G Chadwick officer: Chief Operating Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
Bruce N. Jacobs officer: Chief Financial Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Bruce Booth director 890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Atlas Venture Fund X, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Leigh Morgan director KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472
John Maraganore director 75 SIDNEY ST, CAMBRIDGE MA 02139
Nello Mainolfi director, officer: President and CEO C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Jared Gollob officer: Chief Medical Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Richard Chesworth officer: Chief Scientific Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Elaine Caughey officer: Chief Business Officer C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472